Published in Lancet on April 09, 1994
Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris. BMJ (1994) 4.49
Coronary artery perforation during percutaneous intervention: incidence and outcome. Heart (2002) 1.53
A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A (1998) 1.46
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest (1996) 1.39
Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol (2000) 1.38
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest (1997) 1.37
Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv (2010) 1.30
Integrin affinity modulation in angiogenesis. Cell Cycle (2007) 1.17
The role of alphav integrins during angiogenesis. Mol Med (1998) 1.03
The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/calmodulin- dependent protein kinase II. J Clin Invest (1997) 1.02
Polyethylene glycol diisocyanate decreases platelet deposition after balloon injury of rabbit femoral arteries. J Thromb Thrombolysis (2002) 0.99
Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. J Vasc Surg (2007) 0.97
Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. J Clin Invest (1999) 0.92
New directions in anticoagulant and antiplatelet treatment. Br Heart J (1995) 0.91
The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest (1996) 0.88
Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions. Semin Intervent Radiol (2010) 0.87
Clinical and angiographic outcome after conventional angioplasty with optional stent implantation compared with direct stenting without predilatation. Heart (2002) 0.85
Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Br J Pharmacol (2001) 0.83
Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst J (1995) 0.83
Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives. Ther Clin Risk Manag (2014) 0.83
Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Drug Des Devel Ther (2010) 0.81
Recent advances. Cardiology. BMJ (1998) 0.79
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention. Curr Control Trials Cardiovasc Med (2001) 0.79
Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. Circ Cardiovasc Interv (2012) 0.78
Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci U S A (2001) 0.78
High P-selectin expression and low CD36 occupancy on circulating platelets are strong predictors of restenosis after coronary stenting in patients with coronary artery disease. Heart Vessels (2007) 0.77
Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding. Int J Angiol (2014) 0.77
The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary. Curr Cardiol Rev (2008) 0.77
Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Br J Clin Pharmacol (2000) 0.77
Recent advances in ischaemic heart disease. Postgrad Med J (2000) 0.75
Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. Curr Cardiol Rev (2012) 0.75
Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Can J Cardiol (2006) 0.75
Antiplatelet use in interventional cardiology. Postgrad Med J (2000) 0.75
Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy. Tex Heart Inst J (1998) 0.75
Abbreviations in journals. Lancet (1994) 0.75
Use of antiplatelet inhibitors in peripheral vascular interventions. Semin Intervent Radiol (2005) 0.75
Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention. Korean J Intern Med (2003) 0.75
The role of coronary angioplasty and stenting in acute myocardial infarction. Postgrad Med J (1999) 0.75
Myocardial revascularization. Historical considerations. Tex Heart Inst J (1994) 0.75
Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. Proc AMIA Annu Fall Symp (1997) 0.75
Gene therapy to restore prostacyclin presence to injured endothelium. Trans Am Clin Climatol Assoc (1995) 0.75
Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy. J Thromb Thrombolysis (1995) 0.75
The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA (1996) 17.62
Evaluating the yield of medical tests. JAMA (1982) 14.05
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Regression modelling strategies for improved prognostic prediction. Stat Med (1984) 7.09
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med (1997) 5.80
Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med (1993) 5.59
Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med (1996) 5.51
A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50
Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med (2001) 4.85
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1999) 4.15
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med (1995) 3.69
Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med (1991) 3.63
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med (1992) 3.39
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Scorecard cardiovascular medicine. Its impact and future directions. Ann Intern Med (1994) 3.32
Job strain and the prevalence and outcome of coronary artery disease. Circulation (1995) 3.22
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation (1998) 3.11
The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med (1995) 3.08
Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA (1992) 3.06
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Clinical data bases. Accomplishments and unrealized potential. Med Care (1985) 2.83
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1996) 2.81
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation (2001) 2.77
Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. J Am Coll Cardiol (1988) 2.59
Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation (1997) 2.55
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med (1997) 2.52
Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med (1984) 2.49
Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42
The American College of Cardiology National Database: progress and challenges. American College of Cardiology Database Committee. J Am Coll Cardiol (1997) 2.31
Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet (1997) 2.30
Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. JAMA (2001) 2.29
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. J Am Coll Cardiol (1999) 2.24
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation (1991) 2.23
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23
Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation (1993) 2.16
Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation (2001) 2.12
Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol (1996) 2.11
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09
Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation (1997) 2.09
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry. Am J Cardiol (1992) 2.08
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08
Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol (1996) 2.07
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06
Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol (1990) 2.06
Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation (1995) 2.06
Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: initial U.S. feasibility trial using the Duett vascular closure device. Catheter Cardiovasc Interv (2000) 2.04
The last word on GUSTO, for now. Ann Intern Med (1994) 2.02
Pulsatile varicose veins. J R Soc Med (2000) 1.99
Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med (1987) 1.98
Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation (1994) 1.91
Why endovascular therapy should be utilized before surgical bypass for femoropopliteal occlusive disease. J Invasive Cardiol (2001) 1.91
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1990) 1.90
Absence of sex bias in the referral of patients for cardiac catheterization. N Engl J Med (1994) 1.90
Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury. Circulation (1986) 1.88
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977. Semin Arthritis Rheum (1979) 1.87
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83
Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol (1992) 1.82
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.80